Lupin receives USFDA nod for anti-bacterial tablets

Updated - September 22, 2016 05:25 pm IST

Published - September 06, 2016 11:17 pm IST - MUMBAI:

Lupin’s U.S. subsidiary, Gavis Pharmaceuticals LLC, USA, has received tentative approval for its Moxifloxacin Hydrochloride Tablets, 400 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Bayer Healthcare Pharmaceuticals Inc.’s Avelox Tablets, 400 mg in the US, Lupin said in a statement. Avelox had U.S. sales of $ 30.1 million. Meanwhile, Lupin has received tentative approval for its Silodosin Capsules, 4 mg and 8 mg from the USFDA to market a generic version of Allergan Sales, LLC's RapafloCapsules, 4 mg and 8 mg. Rapaflo had US sales of $228.7 million. — Special Correspondent

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.